📇 Rhumatologue · BAYEUX · (14) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Référence presse grand public
Cité 6 fois dans les médias — pédagogie reconnue
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
150.8 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
7
7 articles ont été cités au moins 7fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
402
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
16
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
7
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier de la Côte Basque
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer
2024ArticleJournal of Thoracic Oncology
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study
2024ArticleJournal of Clinical Oncology
High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease
2018ArticleClinical Gastroenterology and Hepatology
Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab
2017ArticleBritish Journal of Clinical Pharmacology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CENTRE HOSPITALIER - AUNAY-BAYEUX
13 R DE NESMOND BP 142, 14400 BAYEUX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Actu.fr · 18/03/2019
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPTW9hYlFaUE5zb29LM3F5R2Q1c1QzM19seGlVX3Q2RXB3RWJqcGd2VkhvcTZ6cXpUcnFENU5LeDdNUGg0dTh6cVJPTHo3VUhQaUE5LVE3NlFkODY2X0FfMHg4Mk5tNEhmSGtoWFVjbUM1R1BxUWN3ZE4zc3l6eG9CSnI5bGh3X05XZ1RXM0QxRzNhLVZCTWZtU3VwVW1jeG1aSVdzbDlGOHFSczR6LVB0Ums3TkpYZUo3Wl
📰 Ouest-France · 20/12/2023
<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxQdE1HU0RjU2JQTVZWS1FNNXpxTFpoaHlwLU05ZWR6VHNBRWZQVVFOSkVXWU5QSGJld3BndHZ4blNrTTZaMVVCall2WkFSSU1Ncm1iVDFadUo1cVBfZWpVMVotV0FrZzF4b3NPcFJMVW0wVkFzUjlyZktocF9ORkx1empjdW9EVUMwb2c3SXR1ay1iTUhHSGRzajJpd1lmRWNTLUl0N1JXYkVudlZKajB5YmNPR2tuSFZZTl
📰 Ouest-France · 13/03/2018
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPNWJwT3BnZk9UbGpqOGdiV2FVZjY5eGptN2Y3NWtXTmxqNlVUQ3NzT2M2TGNZUnZwSEx4V29ReG85RmFkQnNTX1I3bjRaYXAyUFRZYUlBWTVib2ppNmQzak1MWW1Dd3pUUHdkWTlhV0RnSHM5cEZSS3ZMS2N6QnFYMkZ2aEFkcXpkQkIwMTRodF9YclR5UU9ZblR3eUJnTFNWZUE?oc=5" target="_blank">Bayeux.
📰 Actu.fr · 10/03/2020
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPR1diVmdtT05ucHcxcGUzRDNuaHZkUl84My1QbmpOZGRhN2x3dmZiMHI1VXdENzJqRzVQel9GMkRZb0hoSnZIT0twU05aZ1VKMlhlUTliMktwZnJzZkp4Vl9pM3VtSXRXb3g4OGN2X05lN2xKdmVTemFwVlQxQmY1X1lPUkV5dndZY3pVZDZmbmxmQQ?oc=5" target="_blank">À Bayeux : « La cancérologie,
📰 Ouest-France · 13/12/2023
<a href="https://news.google.com/rss/articles/CBMikgJBVV95cUxPZmpTQk9BTjJBR3g2V3BLTWVWYzdjYzdxdjVqaHUzWnhkLWlvd2lzN1p3cE1xeEx1UFN1R2poNkt3bm12V1RPZmxyNmlkQks4ZmVYb0UxeFc4Tm1VQzk0azNWQTM5V0VsLXYyaWdfbWFpamRUenpvQXpGck8zWTlpcExKZVpaeGlFa1RCOEpIVWY4V0hDY09UbXhSLUotaGt6VVMxUXRmcmNjY29LTjdZZWtyangzcW02ZT
📰 Ouest-France · 11/01/2016
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPNmo5XzBEQ3dnZEV1bm5MZEFIN2NibFdlOFhNakR5amh5RkFCeEJUdXN4RXNvQWEzYmlqX1V5WVR2aFhHSlZYQkE0Nkt4ZFU1X3JzT3JhUEY3ek40Q2VoUmVObEVfNWNqYnpuWjlHZ0lfQjRfNkl0MkxPUW1nMU1HeEdIODhST2M2ZGw5bDBoQnJqUWJwdW9FZGtsT2pXWlZaVE1TUzNSU253c1pQaTIxLQ?oc=5" targe
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
PURPOSE GEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus gemcitabine alone as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received 5-fluorouracil, oxaliplatin, and irinotecan. METHODS Patients with histologically or cytologically confirmed mPDAC were randomly assigned (2:1) to receive GEMPAX (paclitaxel 80 mg/m2 + gemcitabine 1,000 mg/m2; IV; once at day (D) 1, D8, and D15/arm A) or gemcitabine (arm B) alone once at D1, D8, and D15 every 28 days until progression, toxicity, or patient's decision. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), objective response rate (ORR), quality of life, and safety. RESULTS Overall, 211 patients (median age, 64 [30-86] years; 62% male) were included. After a median study follow-up for alive patients of 13.4 versus 13.8 months in arm A versus arm B, the median OS (95% CI) was 6.4 (5.2 to 7.4) versus 5.9 months (4.6 to 6.9; hazard ratio [HR], 0.87 [0.63 to 1.20]; P = 0.4095), the median PFS was 3.1 (2.2 to 4.3) versus 2.0 months (1.9 to 2.3; HR, 0.64 [0.47 to 0.89]; P = 0.0067), and the ORR was 17.1% (11.3 to 24.4) versus 4.2% (0.9 to 11.9; P = 0.008) in arm A versus arm B, respectively. Overall, 16.7% of patients in arm A and 2.9% in arm B discontinued their treatment because of adverse events (AEs). One grade 5 AE associated with both gemcitabine and paclitaxel was reported in arm A (acute respiratory distress), and 58.0% versus 27.1% of patients experienced grade ≥3 treatment-related AEs in arm A versus arm B, among which 15.2% versus 4.3% had anemia, 15.9% versus 15.7% had neutropenia, 19.6% versus 4.3% had thrombocytopenia, 10.1% versus 2.9% had asthenia and 12.3% versus 0.0% had neuropathy. CONCLUSION While GEMPAX did not meet the primary end point of OS versus gemcitabine alone in patients with mPDAC in the second-line setting, both PFS and ORR were significantly improved.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025
British journal of clinical pharmacology · 2017
AimCetuximab is an anti‐epidermal growth factor receptor antibody used for the treatment of metastatic colorectal cancer and head and neck cancer. Hypersensitivity reactions (HSRs) are associated with cetuximab use. The aim of the study was to evaluate the utility of anti‐cetuximab immunoglobulin E (IgE) detection in order to identify patients at risk of HSR to cetuximab.MethodsWe included patients ready to receive a first cetuximab infusion in a prospective cohort carried out at nine French centres. Pretreatment anti‐cetuximab IgE levels were measured. We compared the proportion of severe HSRs in the low anti‐cetuximab IgE levels (≤29 IgE arbitrary units) subgroup with that in a historical cohort of 213 patients extracted from a previous study.ResultsOf the 301 assessable patients (mean age: 60.9 ± 9.3 years, head‐and‐neck cancer: 77%), 66 patients (22%) had high anti‐cetuximab IgE levels, and 247 patients received cetuximab (including 38 with high anti‐cetuximab levels). Severe HSRs occurred in eight patients (five grade 3 and three grade 4). The proportion of severe HSRs was lower in the low anti‐cetuximab IgE levels subgroup vs. the historical cohort (3/209 [1.4%] vs. 11/213 [5.2%], odds ratio, 0.27, 95% confidence interval, 0.07–0.97), and higher in high vs. low anti‐cetuximab IgE levels subgroup (5/38 [13.2%] vs. 3/209 [1.4%]; odds ratio, 10.4, 95% confidence interval, 2.4–45.6). Patients with severe HSRs had higher anti‐cetuximab IgE levels than patients without reaction (median, 45 vs. 2 IgE arbitrary units, P = 0.006).ConclusionsDetection of pretreatment anti‐cetuximab IgE is feasible and helpful to identify patients at risk of severe cetuximab‐induced HSRs.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025 · Journal Article
Swalduz A, Schiffler C, Curcio H, Ambasager B, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Randomized Controlled Trial
De La Fouchardière C, Malka D, Cropet C, Chabaud S, et al.
British journal of clinical pharmacology · 2017 · Journal Article
Dupont B, Mariotte D, Dugué AE, Clarisse B, et al.